2021-2022 Top 10 Best Papers Selected by Cancer Drug Resistance
The Editorial team of Cancer Drug Resistance, in collaboration with ten Editorial Board Members from institutions including the National Cancer Institute (NCI) in the USA, University of California at Los Angeles in the USA, King's College London in the UK, Virginia Commonwealth University in the USA, Wake Forest School of Medicine in the USA, and the University of Macau in China, etc., selected the top 10 most popular high-quality articles from the 142 articles published between 2021 to 2022. The criteria of the selection include originality, scientific rigor, completeness, attractiveness to readers, significance to the research community, overall quality, and actual data. Additionally, the 10 selected articles cover different research fields, such as triple-negative breast cancer, lung cancer, colorectal cancer, prostate cancer, glioblastoma, overcoming cancer drug resistance with nanodrug delivery systems, etc.
The corresponding authors of the 10 selected articles are from Virginia Tech Carilion School of Medicine in the USA, Mayo Clinic in the USA, Vall d’Hebron Institut de Recerca in Spain, University of the Sciences in the USA, National Research Council in Italy, LSU Health Sciences Center in the USA, Fudan University in China, University of Calabria in Italy, Imperial College London in the UK, and Iwate Medical University in Japan.
These articles may be helpful for your recent and future research as they provide insights into the field of cancer resistance. The 10 articles are listed below. Welcome everyone to read, share, and forward these excellent articles!
1. Mechanisms of temozolomide resistance in glioblastoma - a comprehensive review
Corresponding Author: Prof. Sandeep Mittal from Virginia Tech Carilion School of Medicine, USA.
Cite this article: Singh N, Miner A, Hennis L, Mittal S. Mechanisms of temozolomide resistance in glioblastoma - a comprehensive review. Cancer Drug Resist 2021;4:17-43. http://dx.doi.org/10.20517/cdr.2020.79
Cited time: 72 times in Web of Science
Free to read: https://www.oaepublish.com/articles/cdr.2020.79
2. Resistance to venetoclax and hypomethylating agents in acute myeloid leukemia
Corresponding Authors: Dr. Antoine N. Saliba and Dr. Scott H. Kaufmann, Division of Oncology Research, Mayo Clinic, USA.
Cite this article: Saliba AN, John AJ, Kaufmann SH. Resistance to venetoclax and hypomethylating agents in acute myeloid leukemia. Cancer Drug Resist 2021;4:125-42. http://dx.doi.org/10.20517/cdr.2020.95
Cited time: 35 times in Web of Science
Free to read: https://www.oaepublish.com/articles/cdr.2020.95
3. Perspectives of nano-carrier drug delivery systems to overcome cancer drug resistance in the clinics
Corresponding Authors: Dr. Petra Gener and Prof. Simo Schwartz Jr, from CIBBIM-Nanomedicine, Vall d’Hebron Institut de Recerca, Spain.
Cite this article: Ulldemolins A, Seras-Franzoso J, Andrade F, Rafael D, Abasolo I, Gener P, Schwartz Jr S. Perspectives of nano-carrier drug delivery systems to overcome cancer drug resistance in the clinics. Cancer Drug Resist 2021;4:44-68. http://dx.doi.org/10.20517/cdr.2020.59
Cited times: 25 times in Web of Science
Free to read: https://www.oaepublish.com/articles/cdr.2020.59
4. Regulation of cancer stem cells in triple negative breast cancer
Corresponding Author: Dr. Bela Peethambaran from The University of the Sciences, USA.
Cite this article: Fultang N, Chakraborty M, Peethambaran B. Regulation of cancer stem cells in triple negative breast cancer. Cancer Drug Resist 2021;4:321-42. http://dx.doi.org/10.20517/cdr.2020.106
Cited times: 14 times in Web of Science
Free to read: https://www.oaepublish.com/articles/cdr.2020.106
5. Metabolic reprogramming as an emerging mechanism of resistance to endocrine therapies in prostate cancer
Corresponding Author: Dr. Giorgia Zadra from National Research Council, Italy.
Cite this article: Chetta P, Zadra G. Metabolic reprogramming as an emerging mechanism of resistance to endocrine therapies in prostate cancer. Cancer Drug Resist 2021;4:143-62. http://dx.doi.org/10.20517/cdr.2020.54
Cited time: 11 times in Web of Science
Free to read: https://www.oaepublish.com/articles/cdr.2020.54
6. Tousled-like kinase 1: a novel factor with multifaceted role in mCRPC progression and development of therapy resistance
Corresponding Author: Dr. Arrigo De Benedetti from LSU Health Sciences Center, USA.
Cite this article: Khalil MI, De Benedetti A. Tousled-like kinase 1: a novel factor with multifaceted role in mCRPC progression and development of therapy resistance. Cancer Drug Resist 2022;5:93-101. http://dx.doi.org/10.20517/cdr.2021.109
Cited time：5 times in Web of Science
Free to read: https://www.oaepublish.com/articles/cdr.2021.109
7. Tumor-derived exosomes: immune properties and clinical application in lung cancer
Corresponding Author: Dr. Pengfei Zhang from Fudan University, China.
Cite this article: Wu J, Li S, Zhang P. Tumor-derived exosomes: immune properties and clinical application in lung cancer. Cancer Drug Resist 2022;5:102-13. http://dx.doi.org/10.20517/cdr.2021.99
Cited time: 5 times in Web of Science
Free to read: https://www.oaepublish.com/articles/cdr.2021.99
8. Aberrant Notch signaling in gliomas: a potential landscape of actionable converging targets for combination approach in therapies resistance
Corresponding Author: Prof. Francesca De Amicis from University of Calabria, Italy.
Cite this article: D’Amico M, De Amicis F. Aberrant Notch signaling in gliomas: a potential landscape of actionable converging targets for combination approach in therapies resistance. Cancer Drug Resist 2022;5:939-53. http://dx.doi.org/10.20517/cdr.2022.46
Cited time: 3 times in Web of Science
Free to read: https://www.oaepublish.com/articles/cdr.2022.46
9. Targeting the PI3K/AKT/mTOR pathway in epithelial ovarian cancer, therapeutic treatment options for platinum-resistant ovarian cancer
Corresponding Author: Dr. Paula Cunnea from Imperial College London, UK.
Cite this article: Rinne N, Christie EL, Ardasheva A, Kwok CH, Demchenko N, Low C, Tralau-Stewart C, Fotopoulou C, Cunnea P. Targeting the PI3K/AKT/mTOR pathway in epithelial ovarian cancer, therapeutic treatment options for platinum-resistant ovarian cancer. Cancer Drug Resist 2021;4:573-95. http://dx.doi.org/10.20517/cdr.2021.05
Cited time: 18 times in Web of Science
Free to read: https://www.oaepublish.com/articles/cdr.2021.05
10. Cellular irinotecan resistance in colorectal cancer and overcoming irinotecan refractoriness through various combination trials including DNA methyltransferase inhibitors: a review
Corresponding Author: Prof. Shogo Ozawa from Iwate Medical University, Japan.
Cite this article: Ozawa S, Miura T, Terashima J, Habano W. Cellular irinotecan resistance in colorectal cancer and overcoming irinotecan refractoriness through various combination trials including DNA methyltransferase inhibitors: a review. Cancer Drug Resist 2021;4:946-64. http://dx.doi.org/10.20517/cdr.2021.82
Cited time: 10 times in Web of Science
Free to read: https://www.oaepublish.com/articles/cdr.2021.82
About us:
CDR is indexed in PubMed Central (PMC), ESCI, and Scopus (CiteScoreTracker 2022=5.5) and is the first and only gold open-access journal in the field of cancer drug resistance. We will receive our first Impact Factor in June 2023. The citation data in the first quarter of 2023 is outstanding, and it is expected to obtain excellent results in 2023. The journal publishes research articles, reviews, case reports, commentaries and letters on pharmacological aspects of drug resistance and its reversal, including drug design, drug delivery, drug distribution and cellular drug resistance. CDR consistently adheres to the high standards of international publishing principles. All published articles have undergone strict peer review and have been recognized by scholars both domestically and internationally. The average turnaround time of CDR's manuscripts was around two months in 2022. We sincerely welcome researchers in this field to submit your valuable manuscripts to our journal.
